William Demant receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | DEMANT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDEMANTPeersSector | |
|---|---|---|---|---|
P/E Ratio | 30.1x | 26.7x | −0.2x | |
PEG Ratio | −1.03 | −0.26 | 0.00 | |
Price/Book | 6.5x | 5.7x | 2.6x | |
Price / LTM Sales | 3.0x | 2.8x | 2.7x | |
Upside (Analyst Target) | 3.9% | 26.6% | 68.5% | |
Fair Value Upside | Unlock | 18.4% | 11.5% | Unlock |
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.